Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT538 + avelumab
- Development stage
- Unknown
- Lead developer
- Fate Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**FT538 + avelumab** is a combination investigational therapy comprising FT538, an engineered induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell product, and avelumab, a PD-L1-blocking monoclonal antibody. FT538 cells are genetically modified to have a high-affinity, non-cleavable CD16 Fc receptor to optimize antibody-dependent cellular cytotoxicity (ADCC), an IL-15/IL-15 receptor fusion to enhance cell persistence, and a CD38 knockout for improved metabolic fitness. Avelumab is a fully human IgG1 monoclonal antibody targeting PD-L1, enabling immune checkpoint blockade and also mediating ADCC via NK cells. This combination is designed to potentiate immune-mediated killing of cancer cells in patients with advanced solid tumors, especially those expressing PD-L1, and has shown preliminary safety and efficacy in phase I clinical trials[1][2][4].
- Other names
- FT538FT-538FT 538avelumabBavencio
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)FCGR3B (Fc gamma receptor III)CD274 (Programmed cell death protein 1 ligand 1)CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on FT538 + avelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT538 + avelumab.